medigraphic.com
ISSN 1561-3070 (Electronic)

2020, Number 4

<< Back Next >>

Rev Cub Oftal 2020; 33 (4)

Systemic diseases and glaucoma

Obret MI, Díaz ÁY, Sánchez AL, Cárdenas CD, Fumero GF

Language: Spanish
References: 25
Page: 1-15
PDF size: 375.37 Kb.


ABSTRACT

Glaucoma, also known as the "silent thief of sight", is the second leading cause of irreversible blindness worldwide. Despite the scientific and technological advances achieved in the field, a definitive cure has not been found for this disease. The most evident achievement so far has been the adequate control of intraocular pressure values to prevent the progress of optic nerve damage and its effects on the visual field, as well as irreversible blindness. On many occasions it has been possible to maintain intraocular pressure at optimal values, and even then the disease continues to advance, making us wonder what went wrong and why this happens. It should not be forgotten that the optic nerve is not the only organ affected by this condition. There is evidence that damage extends from retinal ganglion cells to the lateral geniculate body and the visual cortex in cerebral hemispheres. Spasm, ischemia or low flow phenomena trigger biochemical reactions, oxidative stress and other processes contributing to the development of this neuropathy. With the purpose of evaluating glaucoma patients in greater depth, a review was conducted about the influence of a number of very common systemic diseases on glaucomatous optic neuropathy.


REFERENCES

  1. Barría F, Jiménez Román J. Latin american guide to primary open angle glaucoma forthe general ophthalmologist. Organización Panamericana de la Salud; 2019 [acceso: 03/12/2020]. Disponible en: https://www. paao. orghttps://www. iapb. org

  2. Sarwat S, Bruce Shields M. Glaucoma and Systemic Diseases. Surv Ophthalmol. 2010;55(1):64-77.

  3. Melgarejo JD, Lee JH, Petitto M, Yépez JB, Murati FA, et al. Glaucomatous OpticNeuropathy Associated with Nocturnal Dip in Blood Pressure. Ophthalmology 2018;125(6):807-14.

  4. Wang S, Bao X. Hyperlipidemia, blood lipid level, and the risk of glaucoma: A Meta-Analysis. Invest Ophthalmol Vis Sci. 2019;60:1028-43.

  5. Talwar N, Musch DC, Stein JD. Association of daily dosage and type of statin agentwith risk of open-angle glaucoma. JAMA Ophthalmol. 2017;135:263-7.

  6. Chen HY, Hsu SY, Chang YC, et al. Association between statin use and open-angleglaucoma in hyperlipidemia patients: a Taiwanese population-based case-control study. Medicine. 2015;94:e2018.

  7. Kang JH, Boumenna T, Stein JD, Khawaja A, Rosner BA, Wiggs JL, Pasquale LR. Association of statin use and high serum cholesterol levels with risk of primary open-angle glaucoma. JAMA Ophthalmol. 2019;137(7). p. 756-65.

  8. Xiao Z, Gong X. Use of statins and risk of reducing glaucoma: Is There a Link. MedPrincip Pract. 2017;26(3):296.

  9. Weiming L, Jiawen L, Yiyi Ch, Yan W, Peirong L. The association between adiposityand the risk of glaucoma: a meta-analysis. Hind J Ophthalmol. 2017;2017. DOI: https://doi. org/10. 1155/2017/9787450

  10. Bülent Ç, İclal ErdEm T, Tuğrul Ç, et al. Effects of obesity on retrobulbar flowhemodynamics: color Doppler ultrasound evaluation. Arq Bras Oftalmol. 2017;80(3):143-7.

  11. Liu CH, Su WW, Shie SS, Cheng ST, Su CW, Ho WJ. Association between peripheralvascular endothelial function and progression of open-angle glaucoma. Medicine 2016;95:e3055.

  12. Vajaranant TS, Pasquale LR. Estrogen deficiency accelerates aging of the optic nerve. Menopause. 2012;19(8):942-7.

  13. Seyed Ahmad R, Ali K, Mahdi M, Negin R, Maryam M, Mohammad M, et al. Theassociation between primary open angle glaucoma and clustered components of metabolic syndrome. Open Ophthalmol J. 2015;9:149-55.

  14. Yokomichi H, Kashiwagi K, Kitamura K, et al. Evaluation of the associations betweenchanges in intraocular pressure and metabolic syndrome parameters: a retrospective cohort study in Japan. BMJ Open. 2016;6:e010360.

  15. JunSeok S, HyunMin K, JunHyuk S. The association between intraocular pressureand different combination of metabolic syndrome components. BMC Ophthalmol. 2016;16:76.

  16. Yu Y,Young Ch,Yun Jin K, Sang Yeoup L, Jeong Gyu L, Byung Mann Ch, et al. Metabolic syndrome as a risk factor for high intraocular pressure: the Korea National Health and Nutrition Examination Survey 2008-2010. Diabetes, Metabolic Syndrome and Obesity. Targ Ther. 2019;12:131-7.

  17. Younhea J, Kyungdo H, Hae-Young L, Chan Kee P, et al. Metabolic health, obesity,and the risk of developing open-angle glaucoma: metabolically healthy obese patients versus metabolically unhealthy but normal weight patients. Diab Metab J. 2019;44(3):414-25. DOI: https://doi. org/10. 4093/dmj. 2019. 0048

  18. Yi-Xin W, Jian-Xin T, Yong Y. The association of intraocular pressure with metabolicsyndrome and its components: a Meta-analysis and systematic review. Int J Ophthalmol. 2019;12(3):510-6.

  19. Chiasseu M. Tau Accumulation, Altered Phosphorylation and Missorting PromoteNeurodegeneration in Glaucoma. J. Neurosci. 2016;36:5785-98.

  20. Yan Z. Elevated intraocular pressure induces amyloid-beta deposition and tauopathyin the lateral geniculate nucleus in a Monkey model of glaucoma. Invest Ophthalmol. 2017;58:5434-43.

  21. Jong Youn M, Hyung Jun K, Yoon Hyung P, Tae Kwann P, Eun-Cheol P, Chan YunK. Association between open-angle glaucoma and the risks of Alzheimer’s and Parkinson’s diseases in South Korea: A 10-year Nationwide Cohort Study. SCIeNtIfIC RePOrtS. 2018;8:11161.

  22. Chan L, Yuan-Hung W, Tsung-Jen W, Yun-Den Sh, Nai-Fang Ch, Li-Nien Ch. Glaucoma, Alzheimer’s disease, and Parkinson’s disease: An 8-Year population-based follow-up study. 2014;9(10):e108938.

  23. Merel SE, Sabine J, Klaus S, Werner P, Nienke M, Thomas T, et al. Ocular and visualdisorders in Parkinson's disease: Common but frequently overlooked. Parkins Rel Disord. 2017. DOI: http://dx. doi. org/10. 1016/j. parkreldis. 2017. 02. 014

  24. Mancino R, Martucci A, Cesareo M, Giannini C, Corasaniti MT, Bagetta G. Glaucoma and Alzheimer Disease: One Age-Related Neurodegenerative Disease of the Brain. Curr Neuropharm. 2018;16:971-7.

  25. Colligris P, Pérez de Lara MJ, Colligris B, Pintor J. Ocular manifestations ofAlzheimer’s and other neurodegenerative diseases: The prospect of the eye as a tool for the early diagnosis of Alzheimer’s disease. Hind J Ophthalmol. 2018;(2018). DOI: https://doi. org/10. 1155/2018/8538573




2020     |     www.medigraphic.com